| NCT06979544 | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | RECRUITING | PHASE3 | 2025-06-16 | 2026-05 | 2026-04 |
| NCT04874350 | A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia | COMPLETED | PHASE2 | 2021-11-30 | 2023-12-18 | 2023-12-18 |
| NCT04685993 | A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial | COMPLETED | PHASE2 | 2020-11-11 | 2022-03-01 | 2022-03-01 |
| NCT04134091 | The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis | COMPLETED | PHASE2 | 2019-08-27 | 2021-06-24 | 2021-06-24 |
| NCT03868059 | Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men | COMPLETED | PHASE3 | 2018-04-30 | 2019-02-21 | 2019-02-19 |
| NCT03242408 | Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) | COMPLETED | PHASE3 | 2017-01 | 2017-07 | 2017-05 |
| NCT03242590 | Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). | COMPLETED | PHASE3 | 2016-12 | 2017-07 | 2017-03 |
| NCT02081300 | Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism | COMPLETED | PHASE3 | 2014-02 | 2015-05 | 2015-05 |